BLU-451 for Lung Cancer
This trial is testing a new cancer drug to see if it is safe and effective. The drug will be given to patients once or twice a day for 21 days.
- Lung Cancer
- Lung Disease
- Bronchial Tumors
- Non-Small Cell Lung Cancer
- EGFR Gene Mutation
- Epidermal Growth Factor Receptor
- Respiratory Diseases
- Epidermal Growth Factor Receptor Mutations
- Brain Tumor
- EGFR Mutation
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are there a considerable number of locations in North America carrying out this trial?
"Patients may be enrolled at 6 different medical centres, including the University of Colorado's Anschutz Cancer Pavilion in Aurora and Laura & Isaac Perlmutter Cancer Center at NYU Langone Health in New York. Additionally, Dana-Farber Cancer Institute is accepting patients for this trial from Boston as well as other sites."
How many individuals have been accepted to participate in this trial?
"Affirmative. Clinicaltrials.gov evidences that this medical trial, which was first posted on March 4th 2022, is actively recruiting and requires 150 participants from 6 distinct clinical sites to complete the study."
Are any new participants being accepted at this time for the research?
"According to the clinicaltrials.gov webpage, this trial is presently enrolling participants with first postings occurring on March 4th 2022 and a recent edit made October 26th of the same year."